<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ETM</journal-id>
<journal-title-group>
<journal-title>Experimental and Therapeutic Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-0981</issn>
<issn pub-type="epub">1792-1015</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/etm.2019.7969</article-id>
<article-id pub-id-type="publisher-id">ETM-0-0-7969</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>KLF4 overexpression decreases the viability, invasion and migration of papillary thyroid cancer cells</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Qianzhu</given-names></name>
<xref rid="af1-etm-0-0-7969" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Xu</surname><given-names>Jian</given-names></name>
<xref rid="af1-etm-0-0-7969" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yong</given-names></name>
<xref rid="af1-etm-0-0-7969" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Liu</surname><given-names>Limin</given-names></name>
<xref rid="af1-etm-0-0-7969" ref-type="aff"/>
<xref rid="c1-etm-0-0-7969" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-etm-0-0-7969">Department of General Surgery, Baoshan District Integrated Traditional Chinese and Western Medicine Hospital, Shanghai 201999, P.R. China</aff>
<author-notes>
<corresp id="c1-etm-0-0-7969"><italic>Correspondence to</italic>: Dr Limin Liu, Department of General Surgery, Baoshan District Integrated Traditional Chinese and Western Medicine Hospital, 181 Youyi Road, Baoshan, Shanghai 201999, P.R. China, E-mail: <email>365424685@qq.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2019</year></pub-date>
<pub-date pub-type="epub">
<day>02</day>
<month>09</month>
<year>2019</year></pub-date>
<volume>18</volume>
<issue>5</issue>
<fpage>3493</fpage>
<lpage>3501</lpage>
<history>
<date date-type="received"><day>19</day><month>10</month><year>2018</year></date>
<date date-type="accepted"><day>06</day><month>06</month><year>2019</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Wang et al.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Kruppel-like factor 4 (KLF4) has been implicated in a number of different types of cancer; however, the role of KLF4 in papillary thyroid cancer remains elusive. The present study aimed to investigate the role of KLF4 in papillary thyroid cancer and its potential underlying molecular mechanisms. The expression of KLF4 in thyroid tumor tissue and adjacent non-cancerous tissues were detected via immunohistochemistry and western blotting. The papillary thyroid cancer cell line, KTC1, was transfected with viruses carrying KLF4 overexpression vectors. The relative expression of KLF4, E-cadherin, N-cadherin, Vimentin, matrix metalloproteinase (MMP)2, MMP9 and collagen was detected via quantitative-PCR. The viability of KTC1 cells was detected using a cell counting kit-8 assay at 24, 48 and 72 h. Cell invasion was examined via a transwell invasion assay. Cell migration was examined via a scratch migration assay at 0 and 24 h. Compared with adjacent non-cancerous tissues, the expression of KLF4 was significantly lower in thyroid tumor tissues. The expression of KLF4 in KTC1 cells were significantly increased compared with the blank or negative control groups. The expression of N-cadherin, MMP2, MMP9 and collagen was significantly decreased in the KLF4 overexpression group. The viability of KTC1 cells was markedly decreased in KLF4 overexpression group at 24, 48 and 72 h when compared with the blank or negative control groups. The invasion of KTC1 cells in the KLF4 overexpression group was markedly decreased. Compared with the negative control group, the KTC1 cell migration in the KLF4 overexpression group was markedly decreased at 24 h. The expression of KLF4 was also significantly lower in thyroid tumor tissues. The cell viability, tumor invasion and migration ability and expression levels of N-cadherin, MMP2, MMP9 and collagen in papillary thyroid cancer cells were markedly decreased with KLF4 overexpression.</p>
</abstract>
<kwd-group>
<kwd>thyroid cancer</kwd>
<kwd>KTC1</kwd>
<kwd>Kruppel-like factor 4</kwd>
<kwd>tumor invasion</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>There were &#x003E;3,000,000 cases of thyroid cancer worldwide in 2015 and 31,900 deaths occurred as a result in the same year (<xref rid="b1-etm-0-0-7969" ref-type="bibr">1</xref>). Thyroid cancer most commonly occurs between the ages of 35 and 65 years, with women affected more frequently (<xref rid="b2-etm-0-0-7969" ref-type="bibr">2</xref>). Papillary thyroid cancer is the most common type of thyroid cancer, accounting for 75&#x2013;85&#x0025; of all thyroid cancer cases (<xref rid="b3-etm-0-0-7969" ref-type="bibr">3</xref>). Its incidence has tripled between 1975 and 2012, with the incidence in 2012 being 14.9 per 100,000 individuals (<xref rid="b4-etm-0-0-7969" ref-type="bibr">4</xref>). Papillary thyroid cancer is the most common thyroid cancer in children, as well as in those who had previously received radiation therapy to the head and neck (<xref rid="b5-etm-0-0-7969" ref-type="bibr">5</xref>). It has also been observed in patients with a family history of syndromes, including multiple endocrine neoplasia type 2 and familial adenomatous polyposis (<xref rid="b6-etm-0-0-7969" ref-type="bibr">6</xref>).</p>
<p>Kruppel-like factor 4 (KLF4) has been implicated in a number of different types of cancer, such as gastric cancer (<xref rid="b7-etm-0-0-7969" ref-type="bibr">7</xref>), lung cancer (<xref rid="b8-etm-0-0-7969" ref-type="bibr">8</xref>) and colorectal cancer (<xref rid="b9-etm-0-0-7969" ref-type="bibr">9</xref>). MicroRNA (miR)-7 has been previously demonstrated to suppress the metastasis of breast cancer stem-like cells into the brain via KLF4 modulation (<xref rid="b10-etm-0-0-7969" ref-type="bibr">10</xref>). Epigenetic inactivation of KLF4 has been reported to be associated with the progression and early recurrence of urothelial cancer (<xref rid="b11-etm-0-0-7969" ref-type="bibr">11</xref>). The KLF4/Musashi 2 signaling pathway is also known to regulate the growth and metastasis of pancreatic cancer (<xref rid="b12-etm-0-0-7969" ref-type="bibr">12</xref>). Additionally, KLF4 was revealed to suppress the proliferation of estrogen-dependent breast cancer by inhibiting the transcriptional activity of estrogen receptor-&#x03B1; (<xref rid="b13-etm-0-0-7969" ref-type="bibr">13</xref>). miR-25 has been reported to enhance non-small cell lung cancer cell migration and invasion by inhibiting KLF4 via the extracellular signal-regulated kinase (ERK) signaling pathway (<xref rid="b14-etm-0-0-7969" ref-type="bibr">14</xref>). The progestin-induced suppression of miR-29 has been demonstrated to promote the dedifferentiation of breast cancer cells via KLF4 (<xref rid="b15-etm-0-0-7969" ref-type="bibr">15</xref>). However, the role of KLF4 in papillary thyroid cancer remains elusive.</p>
<p>E-cadherin is an adhesion molecule that suppresses the invasion of various tumor cells (<xref rid="b16-etm-0-0-7969" ref-type="bibr">16</xref>). N-cadherin is also a transmembrane protein that functions to mediate cell-cell adhesion (<xref rid="b17-etm-0-0-7969" ref-type="bibr">17</xref>). The co-expression of E-cadherin and Vimentin is associated with the invasion and metastasis of breast cancer (<xref rid="b18-etm-0-0-7969" ref-type="bibr">18</xref>). Additionally, matrix metalloproteinase (MMP) 2 was revealed to be suppressed by regulatory T cells and was determined to be involved the regulation of urinary bladder cancer cell invasion (<xref rid="b19-etm-0-0-7969" ref-type="bibr">19</xref>). The gene expression of MMP9 is regulated by epigenetic modifications in breast cancer (<xref rid="b20-etm-0-0-7969" ref-type="bibr">20</xref>). Collagen was also revealed to be elevated in the serum of patients with non-small cell lung cancer (<xref rid="b21-etm-0-0-7969" ref-type="bibr">21</xref>). However, how KLF4 affects the expression of E-cadherin, N-cadherin, Vimentin, MMP2, MMP9 and collagen in papillary thyroid cancer remains unclear.</p>
<p>Therefore, the present study aimed to investigate the role of KLF4 in papillary thyroid cancer and to determine potential underlying molecular mechanisms.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Reagents and patients</title>
<p>Primers and probes, TRIzol<sup>&#x00AE;</sup> reagent, SuperScript III Reverse Transcriptase, SYBR qPCR mix kit was purchased from Invitrogen; Thermo Fisher Scientific, Inc. DMEM was purchased from Gibco (Thermo Fisher Scientific, Inc.).</p>
<p>Thyroid cancer tissues together with the adjacent non-tumor tissue were surgically removed from 8 patients who were admitted to Baoshan District Integrated Traditional Chinese and Western Medicine Hospital (Shanghai, China) between December 2016 and November 2017. The distance between adjacent non-tumor tissue and the boundary of the cancer tissue was ~1 cm. All patients were diagnosed with papillary thyroid cancer and their clinicopathological characteristics were recorded (<xref rid="tI-etm-0-0-7969" ref-type="table">Table I</xref>) (<xref rid="b22-etm-0-0-7969" ref-type="bibr">22</xref>,<xref rid="b23-etm-0-0-7969" ref-type="bibr">23</xref>). After the study was explained, all patients provided written informed consent. The present study was approved by the Institutional Research Board of Baoshan District Integrated Traditional Chinese and Western Medicine Hospital (Shanghai, China).</p>
</sec>
<sec>
<title>Immunohistochemistry (IHC)</title>
<p>Tumor tissues and adjacent non-tumor tissues were embedded in paraffin and cut into slides (5 &#x00B5;m thick). Slides were fixed in 4&#x0025; paraformaldehyde for 10 min at room temperature, blocked with 5&#x0025; bovine serum albumin (Bio-west, Inc.) at room temperature for 30 min and incubated with primary antibodies against KLF4 (1:500; cat. no. Bs-1064R; Bioss Antibodies, Inc.) at 4&#x00B0;C overnight. Following overnight incubation, slides were washed with PBS and incubated in the dark with FITC-conjugated goat anti-rabbit secondary antibodies (1:1,000; cat. no. ab6717; Abcam) at room temperature for 1 h. Slides were subsequently washed with PBS (3 times; each, 30 sec). Slides were prepared with mounting media and Antifades (Invitrogen; Thermo Fisher Scientific, Inc.) and observed using a fluorescence microscope (magnification, &#x00D7;100). The mean intensity, calculated by multiplying the area (size) and average density of fluorescence, was evaluated using Image-Pro Plus software (version 7; Media Cybernetics, Inc.).</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>The protein expression of KLF4 in tumor tissues and adjacent non-cancerous tissues was detected via western blot analysis. In addition, the protein expression of N-cadherin, MMP2, MMP9 and collagen in KTC1 cells were detected via western blotting. Tissues were digested and lysed in lysis buffer (cat. no. P0013; Beyotime Institute of Biotechnology) at 4&#x00B0;C with inhibitors of phosphatase and protease (cat. no. P1045; Beyotime Institute of Biotechnology). The lysis mixture was centrifuged at 4&#x00B0;C for 10 min at 10,000 &#x00D7; g and the supernatant containing cellular proteins was utilized in the following experiments. Protein concentration was determined using a BCA kit. Proteins were separated via SDS-PAGE (10&#x0025; gel; 40 &#x00B5;g loaded per lane; 120 V). Separated proteins were then transferred to PVDF membranes (100 V for 120 min; Beyotime Institute of Biotechnology), which were subsequently blocked with 5&#x0025; non-fat milk at room temperature for 1 h. Membranes were then incubated with the following primary antibodies obtained from Abcam at 4&#x00B0;C overnight: Anti-KLF4, anti-N-cadherin (cat. no. ab18203), anti-MMP2 (cat. no. ab97779), anti-MMP9 (cat. no. ab228402), anti-collagen (cat. no. ab138492), anti-GAPDH (cat. no. ab181602) and anti-&#x03B2;-actin (cat. no. ab8227; all 1:1,000). Membranes were washed with Tris-buffered saline containing Tween 20 and incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies (cat. no. ab6721; 1:2,000; Abcam) at room temperature for 1 h. Membranes were incubated in enhanced chemiluminescence solution (Beyotime Institute of Biotechnology). Images were captured on film (Beyotime Institute of Biotechnology) in a dark room. Experiments were repeated three times. The western blot images were quantified in greyscale using ImageJ software (version 1.5.2; National Institutes of Health).</p>
</sec>
<sec>
<title>Construction of recombinant plasmids and lentiviral packaging</title>
<p>cDNA sequence of KLF4 (NM_004235) was synthesized and subcloned into lentivirus vector pL6.3-CMV-GFPa1-IRES-MCS (Novobio) for lentivirus production. The KLF4 recombinant lentivirus vector, pL6.3-CMV-GFPa1-IRES-KLF4, was confirmed by Sanger sequencing (<xref rid="b24-etm-0-0-7969" ref-type="bibr">24</xref>).</p>
<p>Packaging mix (9 &#x00B5;g; Novobio) and KLF4 recombinant lentiviral plasmids (3 &#x00B5;g) were added into Opti-Minimum Essential Medium (Opti-MEM; Thermo Fisher Scientific Inc.) and mixed. Lipofectamine&#x2122; 2000 (36 &#x00B5;l; Thermo Fisher Scientific Inc.) was mixed with Opti-MEM (1.5 ml) and incubated at room temperature for 5 min. The plasmid solution and diluted Lipofectamine 2000 were then mixed and incubated at room temperature for 5 min. The mixture was added into a culture dish with 293 T cells (Novobio), and cells were cultured for 48 h. Cell supernatants were then collected, centrifuged at 1,500 &#x00D7; g for 10 min at room temperature and filtered. The lentivirus solution was then condensed via centrifugation at 50,000 &#x00D7; g for 2 h at 4&#x00B0;C and re-suspended in DMEM. KLF4 recombinant lentivirus was derived.</p>
<p>The human papillary thyroid carcinoma cell line KTC1 (3&#x00D7;10<sup>5</sup> cells/well in six-well plates) was transfected with the pL6.3-CMV-GFPa1-IRES-KLF4 and pL6.3-CMV-GFPa1-IRES-MCS (control). The transduction MOI was 30. Quantitative PCR (qPCR) was utilized to detect the efficiency of KLF4 overexpression after 48 h. There was no transfection in blank group.</p>
</sec>
<sec>
<title>Reverse transcription-quantitative PCR (RT-qPCR)</title>
<p>The expression of E-cadherin, N-cadherin, Vimentin, MMP2, MMP9 and collagen in KTC1 cells was detected via qPCR. Total RNA was extracted using TRIzol<sup>&#x00AE;</sup> reagent, according to the manufacturer&#x0027;s protocol. A universal cDNA synthesis kit (Invitrogen Thermo Fisher Scientific, Inc.) was utilized for reverse transcription at 42&#x00B0;C for 1 h. Each reaction contained 0.5 &#x00B5;l random hexamers primers (dN6; 0.2 &#x00B5;g/&#x00B5;l; Novobio) and 1 &#x00B5;l SuperScript III reverse transcriptase (200 U/&#x00B5;l). The specific primers used are listed in <xref rid="tII-etm-0-0-7969" ref-type="table">Table II</xref>. PCR was performed using a SYBR qPCR mix kit (Invitrogen; Thermo Fisher Scientific, Inc.). The PCR conditions were as follows: Pre-denaturation at 95&#x00B0;C for 2 min; 40 cycles of denaturation at 95&#x00B0;C for 10 sec annealing at 60&#x00B0;C for 30 sec and polymerization at 70&#x00B0;C for 45 sec. qPCR was performed using a CFX96 Touch&#x2122; Real-Time PCR Detection system (Bio-Rad Laboratories, Inc.). Gene expression was determined and normalized to &#x03B2;-actin. The primer used for rat &#x03B2;-actin was as follows: Forward, 5&#x2032;-AGGGAAATCGTGCGTGAC-3&#x2032; and reverse, 5&#x2032;-CGCTCATTGCCGATAGTG-3&#x2032;. The 2<sup>&#x2212;&#x2206;&#x2206;Cq</sup> method was utilized to measure PCR results (<xref rid="b25-etm-0-0-7969" ref-type="bibr">25</xref>).</p>
</sec>
<sec>
<title>Cell viability assay</title>
<p>The viability of KTC1 cells was measured using a cell counting kit-8 (CCK-8; Dojindo Molecular Technologies, Inc.) cell viability assay at 24, 48 and 72 h after KTC1 cells were transfected with the aforementioned viruses. CCK-8 solution was added to each well and incubated at 37&#x00B0;C for 4 h. The absorbance was subsequently measured using a microplate reader at 490 nm. Relative tumor cell viability rate was calculated by dividing the reading of each group at 24, 48 and 72 h by the baseline reading at 0 h. Experiments were repeated three times.</p>
</sec>
<sec>
<title>Transwell invasion assay</title>
<p>The membrane of the upper compartment was coated with Matrigel (1 g/l; 50 &#x00B5;l), which was allowed to solidify via incubation at 37&#x00B0;C for 1 h. KTC1 cell suspension (1&#x00D7;10<sup>4</sup> cells/ml, 200 &#x00B5;l) in 2&#x0025; DMEM was added to the upper compartment of each Transwell insert, while 800 &#x00B5;l DMEM with 10&#x0025; FBS (HyClone; GE Healthcare Life Sciences) was added to the lower compartment. Cells were incubated at 37&#x00B0;C for 24 h. Subsequently, 4&#x0025; paraformaldehyde was utilized to fix cells on the microporous membrane at room temperature for 30 min. Cells on the lower side of the membrane were stained with 1&#x0025; crystal violet at room temperature for 10 min and washed with PBS twice. Cells were then observed under Olympus IX50 fluorescent microscope (magnification, &#x00D7;400; Olympus Corporation) and the number of cells that had transgressed through the membrane was counted. Relative tumor cell invasion was calculated by dividing the average number of cells that invaded through the membrane in the experimental groups by that in the blank group. Experiments were repeated three times.</p>
</sec>
<sec>
<title>Scratch migration assay</title>
<p>A confluent monolayer of KTC1 cells was used in the scratch migration assay. A marker pen was used to draw a straight line at the back of plate. Pippet tips were utilized to draw scratch lines vertical to the straight line on the second day. PBS was used to wash cells three times and DMEM without serum was added. Images were taken under Olympus IX50 (magnification, &#x00D7;400) and cultured in an incubator with 5&#x0025; CO<sub>2</sub> at 37&#x00B0;C. Images were then taken at 24 h and migration distances were calculated under the same field using Image-Pro Plus software. Migration distance at 24 h relative to 0 h was recorded for both negative control and overexpression groups. Then relative migration distances were normalized to the negative control group.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Experiments were repeated three times. Statistical data was analyzed using GraphPad Prism software (version 5.0; GraphPad Software Inc.). The results are presented as the mean &#x00B1; standard deviation. Differences among more than three groups were compared by a one-way analysis of variance followed by the Bonferroni post-hoc test. Differences between two groups were compared using Student&#x0027;s unpaired t-test. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Expression of KLF4 is significantly lower in thyroid tumor tissue</title>
<p>The expression of KLF4 in thyroid tumor tissue and paracarcinoma tissue was detected by IHC. In the microscopic image of KLF4 staining (<xref rid="f1-etm-0-0-7969" ref-type="fig">Fig. 1</xref>), positive cell nucleus was stained by diaminobenzidine (DAB) and appeared as brown. Negative cell nucleus was stained by hematoxylin and appeared as blue. Compared with adjacent non-cancerous tissue, the protein expression of KLF4 was significantly lower in thyroid tumor tissue (P&#x003C;0.001; <xref rid="f1-etm-0-0-7969" ref-type="fig">Fig. 1</xref>). In addition, the protein expression of KLF4 in tumor and adjacent non-cancerous tissue was detected via western blot analysis. The protein expression of KLF4 was markedly lower in thyroid tumor tissue when compared with adjacent non-cancerous tissues (P&#x003C;0.05; <xref rid="f2-etm-0-0-7969" ref-type="fig">Fig. 2</xref>).</p>
</sec>
<sec>
<title>Confirmation of KLF4 overexpression</title>
<p>KTC1 cells were transfected with viruses carrying KLF4 overexpression vectors. The relative expression of KLF4 was detected via qPCR. The expression of KLF4 in KTC1 cells was significantly increased compared with the blank or negative control groups (P&#x003C;0.001; <xref rid="f3-etm-0-0-7969" ref-type="fig">Fig. 3</xref>).</p>
</sec>
<sec>
<title>Expression of N-cadherin, MMP2, MMP9 and collagen is significantly decreased in the KLF4 overexpression group</title>
<p>The mRNA levels of E-cadherin, N-cadherin, Vimentin, MMP2, MMP9 and collagen in KTC1 cells were detected via qPCR. The protein expression of N-cadherin, MMP2, MMP9 and collagen in KTC1 cells were confirmed by western blotting. Among all the genes screened, the mRNA expression of N-cadherin, MMP2, MMP9 and collagen were significantly decreased in the KLF4 overexpression group when compared with the blank or negative control groups (P&#x003C;0.05 for N-cadherin and MMP2; P&#x003C;0.01 for MMP9; P&#x003C;0.001 for collagen; <xref rid="f4-etm-0-0-7969" ref-type="fig">Fig. 4</xref>). No significant differences were observed in the levels of E-cadherin and Vimentin (<xref rid="f4-etm-0-0-7969" ref-type="fig">Fig. 4</xref>). In addition, the protein expression of N-cadherin, MMP2, MMP9 and collagen were significantly decreased in the KLF4 overexpression group when compared with blank or negative control group (P&#x003C;0.01 for N-cadherin; P&#x003C;0.001 for MMP-2, MMP-9 and collagen; <xref rid="f5-etm-0-0-7969" ref-type="fig">Fig. 5</xref>).</p>
</sec>
<sec>
<title>Viability of papillary thyroid cancer cells is markedly decreased in the KLF4 overexpression group</title>
<p>The viability of KTC1 cells was detected via a CCK-8 assay at 24, 48 and 72 h. The viability of KTC1 cells was markedly decreased in the KLF4 overexpression group at 24, 48 and 72 h when compared with the blank or negative control group (P&#x003C;0.01 for 24 h; P&#x003C;0.001 for 48 and 72 h; <xref rid="f6-etm-0-0-7969" ref-type="fig">Fig. 6</xref>).</p>
</sec>
<sec>
<title>Invasion of papillary thyroid cancer cells in the KLF4 overexpression group is significantly decreased</title>
<p>Cell invasion was investigated using a transwell invasion assay. Compared with the negative control group, the invasion of KTC1 cells in the KLF4 overexpression group were significantly decreased (P&#x003C;0.01; <xref rid="f7-etm-0-0-7969" ref-type="fig">Fig. 7</xref>).</p>
</sec>
<sec>
<title>Migration of papillary thyroid cancer cells in the KLF4 overexpression group is significantly decreased at 24 h</title>
<p>Cell migration ability was examined via a scratch migration assay at 0 and 24 h. Compared with the negative control group, the migration of KTC1 cells in the KLF4 overexpression group was significantly decreased at 24 h (P&#x003C;0.01; <xref rid="f8-etm-0-0-7969" ref-type="fig">Fig. 8</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The present study demonstrated that the expression of KLF4 was significantly lower in thyroid tumor tissue compared with adjacent non-cancerous tissue. The viability, invasion and migration of cells, and the expression of N-cadherin, MMP2, MMP9 and collagen in papillary thyroid cancer cells were markedly decreased following KLF4 overexpression.</p>
<p>KLF4 has been reported to inhibit the proliferation of colorectal cancer cells via NMYC downstream-regulated gene 2 (<xref rid="b26-etm-0-0-7969" ref-type="bibr">26</xref>). Furthermore, KLF4 suppressed estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of the estrogen receptor (<xref rid="b27-etm-0-0-7969" ref-type="bibr">27</xref>). KLF4 has also been demonstrated to inhibit the invasion of lung cancer cells by suppressing secreted protein acidic and cysteine rich gene expression (<xref rid="b27-etm-0-0-7969" ref-type="bibr">27</xref>). F-box protein-32 suppressed the tumorigenesis of breast cancer by targeting KLF4 for proteasomal degradation (<xref rid="b28-etm-0-0-7969" ref-type="bibr">28</xref>). In addition, the long non-coding RNA small nucleolar RNA host gene 5/miR-32 axis was revealed to regulate gastric cancer cell proliferation and migration by targeting KLF4 (<xref rid="b29-etm-0-0-7969" ref-type="bibr">29</xref>). KLF4 and KLF5 regulated the proliferation, apoptosis and invasion of esophageal cancer cells (<xref rid="b30-etm-0-0-7969" ref-type="bibr">30</xref>). Meanwhile, KLF4 was revealed to regulate adult lung tumor-initiating cells and repress K-Ras-mediated lung cancer (<xref rid="b31-etm-0-0-7969" ref-type="bibr">31</xref>). To the best of our knowledge, the present study revealed for the first time that the expression of KLF4 was significantly lower in thyroid tumor tissue when compared with adjacent non-cancerous tissues, and the viability, tumor invasion and migration of papillary thyroid cancer cells were significantly decreased following the overexpression of KLF4. These results may broaden the current understanding of the properties of KLF4, and shed light on possible therapeutic treatment of papillary thyroid cancer.</p>
<p>The present study revealed that the expression of N-cadherin, MMP2, MMP9 and collagen in papillary thyroid cancer cells were significantly decreased when KLF4 was overexpressed. N-cadherin expression in breast cancer has been demonstrated to be associated with an aggressive histological variant of invasive micropapillary carcinoma (<xref rid="b32-etm-0-0-7969" ref-type="bibr">32</xref>). N-cadherin, as a novel prognostic biomarker, was reported to drive the malignant progression of colorectal cancer (<xref rid="b33-etm-0-0-7969" ref-type="bibr">33</xref>). N-cadherin expression was also associated with enhanced invasion in erlotinib-resistant lung cancer cell lines (<xref rid="b34-etm-0-0-7969" ref-type="bibr">34</xref>). In addition, Trop2 has been indicated to enhance the invasion of thyroid cancer by inducing MMP2 via ERK and Janus kinase pathways (<xref rid="b35-etm-0-0-7969" ref-type="bibr">35</xref>). miR-29c suppressed the adhesion of lung cancer cell to the extracellular matrix, as well as metastasis, by targeting MMP2 (<xref rid="b36-etm-0-0-7969" ref-type="bibr">36</xref>). The association between the MMP2-1306 C/T polymorphism and prostate cancer susceptibility was revealed in a meta-analysis based on 3,906 subjects (<xref rid="b37-etm-0-0-7969" ref-type="bibr">37</xref>). Meanwhile, the downregulation of hepatoma-derived growth factor inhibited the migration and invasion of prostate cancer cells by suppressing MMP2 and MMP9 (<xref rid="b38-etm-0-0-7969" ref-type="bibr">38</xref>). miR-133b was reported to inhibit the cell growth, migration and invasion by targeting MMP9 in non-small cell lung cancer (<xref rid="b39-etm-0-0-7969" ref-type="bibr">39</xref>). Furthermore, the selective targeting of collagen IV in the cancer cell microenvironment was revealed to decrease tumor burden (<xref rid="b40-etm-0-0-7969" ref-type="bibr">40</xref>). Losartan loaded liposomes improved the antitumor efficacy of liposomal paclitaxel via the inhibition of collagen in breast cancer (<xref rid="b41-etm-0-0-7969" ref-type="bibr">41</xref>). In the present study, the significantly decreased expression of N-cadherin, MMP2, MMP9 and collagen in papillary thyroid cancer cells following KLF4 overexpression may impair the adhesion of thyroid cancer cells to the extracellular matrix, thus disrupting tumor invasion and migration.</p>
<p>Other factors may also account for the effects of KLF4 overexpression on tumor invasion and migration. KLF4 inhibited tumor growth and metastasis by targeting miR-31 in human hepatocellular carcinoma (<xref rid="b42-etm-0-0-7969" ref-type="bibr">42</xref>). Podocalyxin-like (PODXL) promoted the metastasis of gastric cancer, whereas KLF4 downregulated PODXL and prevented metastasis (<xref rid="b43-etm-0-0-7969" ref-type="bibr">43</xref>). miR-543 was also revealed to promote colorectal cancer proliferation and metastasis by targeting KLF4 (<xref rid="b44-etm-0-0-7969" ref-type="bibr">44</xref>). In addition, KLF4-mediated suppression of CD44 signaling decreased the stemness and metastasis of pancreatic cancer (<xref rid="b45-etm-0-0-7969" ref-type="bibr">45</xref>). Further studies are required to elucidate whether the aforementioned factors modulate the anti-metastasis effects of KLF4 in papillary thyroid cancer.</p>
<p>There are certain limitations to the present study. Normal thyroid cell lines were not used and there was no <italic>in vivo</italic> study. However, the present study detected the expression levels of KLF4 in human thyroid tumor tissue and adjacent normal tissues via IHC and western blotting. The experimental results in human tissues were consistent; therefore, similar experiments in normal thyroid cell lines or animals were not performed, which may or may not reflect the real situations in human.</p>
<p>In conclusion, the present study demonstrated that the expression of KLF4 was significantly lower in thyroid tumor tissue. The cell viability, tumor invasion and migration, and expression levels of N-cadherin, MMP2, MMP9 and collagen in papillary thyroid cancer cells were markedly decreased with the overexpression of KLF4. Although further research is required to elucidate the underlying molecular mechanisms, the present study may provide the foundations for future therapeutic measures targeting papillary thyroid cancer.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>The present study was supported by the Baoshan District Science and Technology Commission Fund (grant no. 16-E-10), and Baoshan District Integrated Traditional Chinese and Western Medicine Hospital Fund (grant no. 201603).</p>
</sec>
<sec>
<title>Availability of data and materials</title>
<p>All data generated or analyzed during this study are included in this published article.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>QW, LL and JX designed the experiments. QW and YC carried out the experiments. YC performed the statistical analyses. LL and JX gave advice on how to design and carry out experiments. QW wrote the manuscript, which was revised by the other authors. All authors read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>The present study was approved by the Institutional Research Board of Baoshan District Integrated Traditional Chinese and Western Medicine Hospital. Each participant provided written informed consent.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-etm-0-0-7969"><label>1</label><element-citation publication-type="journal"><article-title>GBD 2015 Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990&#x2013;2015: A systematic analysis for the Global Burden of Disease Study 2015</article-title><source>Lancet</source><volume>388</volume><fpage>1545</fpage><lpage>1602</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31678-6</pub-id><pub-id pub-id-type="pmid">27733282</pub-id></element-citation></ref>
<ref id="b2-etm-0-0-7969"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Identification of &#x03B2;-hydroxybutyrate as a potential biomarker for female papillary thyroid cancer</article-title><source>Bioanalysis</source><volume>11</volume><fpage>461</fpage><lpage>470</lpage><year>2019</year><pub-id pub-id-type="doi">10.4155/bio-2018-0273</pub-id><pub-id pub-id-type="pmid">30892060</pub-id></element-citation></ref>
<ref id="b3-etm-0-0-7969"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>BC</given-names></name><name><surname>Timsina</surname><given-names>L</given-names></name><name><surname>Graham</surname><given-names>R</given-names></name><name><surname>Angelos</surname><given-names>P</given-names></name><name><surname>Haggstrom</surname><given-names>DA</given-names></name></person-group><article-title>Changes in total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer during the past 15 years</article-title><source>Surgery</source><volume>166</volume><fpage>41</fpage><lpage>47</lpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.surg.2019.01.007</pub-id><pub-id pub-id-type="pmid">30904172</pub-id></element-citation></ref>
<ref id="b4-etm-0-0-7969"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galuppini</surname><given-names>F</given-names></name><name><surname>Pennelli</surname><given-names>G</given-names></name><name><surname>Rugge</surname><given-names>M</given-names></name></person-group><article-title>The rising incidence of papillary thyroid cancer: More cancers or more assessments?</article-title><source>Indian J Cancer</source><volume>56</volume><fpage>183</fpage><lpage>184</lpage><year>2019</year><pub-id pub-id-type="doi">10.4103/ijc.IJC_483_18</pub-id><pub-id pub-id-type="pmid">31062744</pub-id></element-citation></ref>
<ref id="b5-etm-0-0-7969"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazaure</surname><given-names>HS</given-names></name><name><surname>Roman</surname><given-names>SA</given-names></name><name><surname>Sosa</surname><given-names>JA</given-names></name></person-group><article-title>Aggressive variants of papillary thyroid cancer: Incidence, characteristics and predictors of survival among 43,738 patients</article-title><source>Ann Surg Oncol</source><volume>19</volume><fpage>1874</fpage><lpage>1880</lpage><year>2011</year><pub-id pub-id-type="doi">10.1245/s10434-011-2129-x</pub-id><pub-id pub-id-type="pmid">22065195</pub-id></element-citation></ref>
<ref id="b6-etm-0-0-7969"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>ML</given-names></name></person-group><article-title>Thyroid cancer genetics: Multiple endocrine neoplasia type 2, non-medullary familial thyroid cancer, and familial syndromes associated with thyroid cancer</article-title><source>Surg Oncol Clin N Am</source><volume>18</volume><fpage>39</fpage><lpage>52</lpage><issue>viii</issue><year>2009</year><pub-id pub-id-type="doi">10.1016/j.soc.2008.08.002</pub-id><pub-id pub-id-type="pmid">19056041</pub-id></element-citation></ref>
<ref id="b7-etm-0-0-7969"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>He</surname><given-names>S</given-names></name></person-group><article-title>Transcription factor KLF4 modulates microRNA-106a that targets Smad7 in gastric cancer</article-title><source>Pathol Res Pract</source><fpage>152467</fpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.prp.2019.152467</pub-id><pub-id pub-id-type="pmid">31146975</pub-id></element-citation></ref>
<ref id="b8-etm-0-0-7969"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuan</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><article-title>Overexpression of the long noncoding RNA TRHDE-AS1 inhibits the progression of lung cancer via the miRNA-103/KLF4 axis</article-title><source>J Cell Biochem</source><month>May</month><day>22</day><year>2019</year><comment>(Epub ahead of print). doi: 10.1002/jcb.29029</comment><pub-id pub-id-type="doi">10.1002/jcb.29029</pub-id><pub-id pub-id-type="pmid">31119790</pub-id></element-citation></ref>
<ref id="b9-etm-0-0-7969"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>VW</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Shroyer</surname><given-names>KR</given-names></name><name><surname>Bialkowska</surname><given-names>AB</given-names></name></person-group><article-title>Increased genetic instability and accelerated progression of colitis-associated colorectal cancer through intestinal epithelium-specific deletion of Klf4</article-title><source>Mol Cancer Res</source><volume>17</volume><fpage>165</fpage><lpage>176</lpage><year>2019</year><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-18-0399</pub-id><pub-id pub-id-type="pmid">30108164</pub-id></element-citation></ref>
<ref id="b10-etm-0-0-7969"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname><given-names>H</given-names></name><name><surname>Xing</surname><given-names>F</given-names></name><name><surname>Pandey</surname><given-names>PR</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Watabe</surname><given-names>M</given-names></name><name><surname>Pai</surname><given-names>SK</given-names></name><name><surname>Mo</surname><given-names>YY</given-names></name><name><surname>Iiizumi-Gairani</surname><given-names>M</given-names></name><name><surname>Hirota</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4</article-title><source>Cancer Res</source><volume>73</volume><fpage>1434</fpage><lpage>1444</lpage><year>2013</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2037</pub-id><pub-id pub-id-type="pmid">23384942</pub-id></element-citation></ref>
<ref id="b11-etm-0-0-7969"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Xia</surname><given-names>D</given-names></name><name><surname>Lang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name></person-group><article-title>Epigenetic inactivation of KLF4 is associated with urothelial cancer progression and early recurrence</article-title><source>J Urol</source><volume>191</volume><fpage>493</fpage><lpage>501</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.juro.2013.08.087</pub-id><pub-id pub-id-type="pmid">24018236</pub-id></element-citation></ref>
<ref id="b12-etm-0-0-7969"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>K</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Quan</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>D</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Xie</surname><given-names>K</given-names></name></person-group><article-title>The novel KLF4/MSI2 signaling pathway regulates growth and metastasis of pancreatic cancer</article-title><source>Clin Cancer Res</source><volume>23</volume><fpage>687</fpage><lpage>696</lpage><year>2017</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-1064</pub-id><pub-id pub-id-type="pmid">27449499</pub-id></element-citation></ref>
<ref id="b13-etm-0-0-7969"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akaogi</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>I</given-names></name><name><surname>Kawasaki</surname><given-names>S</given-names></name><name><surname>Oie</surname><given-names>SH</given-names></name><name><surname>Murayama</surname><given-names>A</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Yanagisawa</surname><given-names>J</given-names></name></person-group><article-title>KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha</article-title><source>Oncogene</source><volume>28</volume><fpage>2894</fpage><lpage>2902</lpage><year>2009</year><pub-id pub-id-type="doi">10.1038/onc.2009.151</pub-id><pub-id pub-id-type="pmid">19503094</pub-id></element-citation></ref>
<ref id="b14-etm-0-0-7969"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name></person-group><article-title>miR-25 enhances cell migration and invasion in non-small-cell lung cancer cells via ERK signaling pathway by inhibiting KLF4</article-title><source>Mol Med Rep</source><volume>17</volume><fpage>7005</fpage><lpage>7016</lpage><year>2018</year><pub-id pub-id-type="pmid">29568911</pub-id></element-citation></ref>
<ref id="b15-etm-0-0-7969"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cittelly</surname><given-names>DM</given-names></name><name><surname>Finlay-Schultz</surname><given-names>J</given-names></name><name><surname>Howe</surname><given-names>EN</given-names></name><name><surname>Spoelstra</surname><given-names>NS</given-names></name><name><surname>Axlund</surname><given-names>SD</given-names></name><name><surname>Hendricks</surname><given-names>P</given-names></name><name><surname>Jacobsen</surname><given-names>BM</given-names></name><name><surname>Sartorius</surname><given-names>CA</given-names></name><name><surname>Richer</surname><given-names>JK</given-names></name></person-group><article-title>Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4</article-title><source>Oncogene</source><volume>32</volume><fpage>2555</fpage><lpage>2564</lpage><year>2012</year><pub-id pub-id-type="doi">10.1038/onc.2012.275</pub-id><pub-id pub-id-type="pmid">22751119</pub-id></element-citation></ref>
<ref id="b16-etm-0-0-7969"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>AS</given-names></name><name><surname>Gumbiner</surname><given-names>BM</given-names></name></person-group><article-title>Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin</article-title><source>J Cell Biol</source><volume>161</volume><fpage>1191</fpage><lpage>1203</lpage><year>2003</year><pub-id pub-id-type="doi">10.1083/jcb.200212033</pub-id><pub-id pub-id-type="pmid">12810698</pub-id></element-citation></ref>
<ref id="b17-etm-0-0-7969"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makrigiannakis</surname><given-names>A</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Blaschuk</surname><given-names>O</given-names></name><name><surname>Coutifaris</surname><given-names>C</given-names></name></person-group><article-title>Follicular atresia and luteolysis. Evidence of a role for N-cadherin</article-title><source>Ann N Y Acad Sci</source><volume>900</volume><fpage>46</fpage><lpage>55</lpage><year>2000</year><pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb06215.x</pub-id><pub-id pub-id-type="pmid">10818391</pub-id></element-citation></ref>
<ref id="b18-etm-0-0-7969"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>N</given-names></name><name><surname>Tokunaga</surname><given-names>E</given-names></name><name><surname>Iimori</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Kitao</surname><given-names>H</given-names></name><name><surname>Saeki</surname><given-names>H</given-names></name><name><surname>Oki</surname><given-names>E</given-names></name><name><surname>Maehara</surname><given-names>Y</given-names></name></person-group><article-title>Epithelial paradox: Clinical significance of coexpression of E-cadherin and vimentin with regard to invasion and metastasis of breast cancer</article-title><source>Clin Breast Cancer</source><volume>18</volume><fpage>e1003</fpage><lpage>e1009</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.clbc.2018.02.002</pub-id><pub-id pub-id-type="pmid">29526677</pub-id></element-citation></ref>
<ref id="b19-etm-0-0-7969"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winerdal</surname><given-names>ME</given-names></name><name><surname>Krantz</surname><given-names>D</given-names></name><name><surname>Hartana</surname><given-names>CA</given-names></name><name><surname>Zirakzadeh</surname><given-names>AA</given-names></name><name><surname>Linton</surname><given-names>L</given-names></name><name><surname>Bergman</surname><given-names>EA</given-names></name><name><surname>Rosenblatt</surname><given-names>R</given-names></name><name><surname>Vasko</surname><given-names>J</given-names></name><name><surname>Alamdari</surname><given-names>F</given-names></name><name><surname>Hansson</surname><given-names>J</given-names></name><etal/></person-group><article-title>Urinary bladder cancer Tregs suppress MMP2 and potentially regulate invasiveness</article-title><source>Cancer Immunol Res</source><volume>6</volume><fpage>528</fpage><lpage>538</lpage><year>2018</year><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-17-0466</pub-id><pub-id pub-id-type="pmid">29588320</pub-id></element-citation></ref>
<ref id="b20-etm-0-0-7969"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klassen</surname><given-names>LMB</given-names></name><name><surname>Chequin</surname><given-names>A</given-names></name><name><surname>Manica</surname><given-names>GCM</given-names></name><name><surname>Biembengut</surname><given-names>IV</given-names></name><name><surname>Toledo</surname><given-names>MB</given-names></name><name><surname>Baura</surname><given-names>VA</given-names></name><name><surname>de O Pedrosa</surname><given-names>F</given-names></name><name><surname>Ramos</surname><given-names>EAS</given-names></name><name><surname>Costa</surname><given-names>FF</given-names></name><name><surname>de Souza</surname><given-names>EM</given-names></name><name><surname>Klassen</surname><given-names>G</given-names></name></person-group><article-title>MMP9 gene expression regulation by intragenic epigenetic modifications in breast cancer</article-title><source>Gene</source><volume>642</volume><fpage>461</fpage><lpage>466</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.gene.2017.11.054</pub-id><pub-id pub-id-type="pmid">29162512</pub-id></element-citation></ref>
<ref id="b21-etm-0-0-7969"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>SH</given-names></name><name><surname>Willumsen</surname><given-names>N</given-names></name><name><surname>Brix</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Manon-Jensen</surname><given-names>T</given-names></name><name><surname>Karsdal</surname><given-names>M</given-names></name><name><surname>Genovese</surname><given-names>F</given-names></name></person-group><article-title>Tumstatin, a matrikine derived from collagen type IV&#x03B1;3, is elevated in serum from patients with non-small cell lung cancer</article-title><source>Transl Oncol</source><volume>11</volume><fpage>528</fpage><lpage>534</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.tranon.2018.02.005</pub-id><pub-id pub-id-type="pmid">29524830</pub-id></element-citation></ref>
<ref id="b22-etm-0-0-7969"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimori</surname><given-names>M</given-names></name><name><surname>Sakauchi</surname><given-names>G</given-names></name></person-group><article-title>TNM classification-thyroid cancer</article-title><source>Gan No Rinsho</source><volume>13</volume><fpage>320</fpage><lpage>322</lpage><year>1967</year><comment>(In Japanese)</comment><pub-id pub-id-type="pmid">5624085</pub-id></element-citation></ref>
<ref id="b23-etm-0-0-7969"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haugen</surname><given-names>BR</given-names></name><name><surname>Alexander</surname><given-names>EK</given-names></name><name><surname>Bible</surname><given-names>KC</given-names></name><name><surname>Doherty</surname><given-names>GM</given-names></name><name><surname>Mandel</surname><given-names>SJ</given-names></name><name><surname>Nikiforov</surname><given-names>YE</given-names></name><name><surname>Pacini</surname><given-names>F</given-names></name><name><surname>Randolph</surname><given-names>GW</given-names></name><name><surname>Sawka</surname><given-names>AM</given-names></name><name><surname>Schlumberger</surname><given-names>M</given-names></name><etal/></person-group><article-title>2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer</article-title><source>Thyroid</source><volume>26</volume><fpage>1</fpage><lpage>33</lpage><year>2016</year><pub-id pub-id-type="doi">10.1089/thy.2015.0020</pub-id><pub-id pub-id-type="pmid">26462967</pub-id></element-citation></ref>
<ref id="b24-etm-0-0-7969"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancini</surname><given-names>P</given-names></name><name><surname>Bonanno Ferraro</surname><given-names>G</given-names></name><name><surname>Iaconelli</surname><given-names>M</given-names></name><name><surname>Suffredini</surname><given-names>E</given-names></name><name><surname>Valdazo-Gonz&#x00E1;lez</surname><given-names>B</given-names></name><name><surname>Della Libera</surname><given-names>S</given-names></name><name><surname>Divizia</surname><given-names>M</given-names></name><name><surname>La Rosa</surname><given-names>G</given-names></name></person-group><article-title>Molecular characterization of human Sapovirus in untreated sewage in Italy by amplicon-based Sanger and next-generation sequencing</article-title><source>J Appl Microbiol</source><volume>126</volume><fpage>324</fpage><lpage>331</lpage><year>2019</year><pub-id pub-id-type="doi">10.1111/jam.14129</pub-id><pub-id pub-id-type="pmid">30315674</pub-id></element-citation></ref>
<ref id="b25-etm-0-0-7969"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref>
<ref id="b26-etm-0-0-7969"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>KLF4 inhibits colorectal cancer cell proliferation dependent on NDRG2 signaling</article-title><source>Oncol Rep</source><volume>38</volume><fpage>975</fpage><lpage>984</lpage><year>2017</year><pub-id pub-id-type="doi">10.3892/or.2017.5736</pub-id><pub-id pub-id-type="pmid">28656310</pub-id></element-citation></ref>
<ref id="b27-etm-0-0-7969"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Hofstetter</surname><given-names>WL</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Pataer</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Fang</surname><given-names>B</given-names></name><name><surname>Swisher</surname><given-names>SG</given-names></name></person-group><article-title>KLF4 inhibition of lung cancer cell invasion by suppression of SPARC expression</article-title><source>Cancer Biol Ther</source><volume>9</volume><fpage>507</fpage><lpage>513</lpage><year>2010</year><pub-id pub-id-type="doi">10.4161/cbt.9.7.11106</pub-id><pub-id pub-id-type="pmid">20215880</pub-id></element-citation></ref>
<ref id="b28-etm-0-0-7969"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>R</given-names></name><name><surname>Ding</surname><given-names>F</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation</article-title><source>Oncogene</source><volume>36</volume><fpage>3312</fpage><lpage>3321</lpage><year>2017</year><pub-id pub-id-type="doi">10.1038/onc.2016.479</pub-id><pub-id pub-id-type="pmid">28068319</pub-id></element-citation></ref>
<ref id="b29-etm-0-0-7969"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Shan</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name></person-group><article-title>The lncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4</article-title><source>FASEB J</source><volume>31</volume><fpage>893</fpage><lpage>903</lpage><year>2016</year><pub-id pub-id-type="doi">10.1096/fj.201600994R</pub-id><pub-id pub-id-type="pmid">27871067</pub-id></element-citation></ref>
<ref id="b30-etm-0-0-7969"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Goldstein</surname><given-names>BG</given-names></name><name><surname>Chao</surname><given-names>HH</given-names></name><name><surname>Katz</surname><given-names>JP</given-names></name></person-group><article-title>KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells</article-title><source>Cancer Biol Ther</source><volume>4</volume><fpage>1216</fpage><lpage>1221</lpage><year>2005</year><pub-id pub-id-type="doi">10.4161/cbt.4.11.2090</pub-id><pub-id pub-id-type="pmid">16357509</pub-id></element-citation></ref>
<ref id="b31-etm-0-0-7969"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Avdiushko</surname><given-names>R</given-names></name><name><surname>Napier</surname><given-names>DL</given-names></name><name><surname>Liu</surname><given-names>AX</given-names></name><name><surname>Neltner</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name></person-group><article-title>KLF4 regulates adult lung tumor-initiating cells and represses K-Ras-mediated lung cancer</article-title><source>Cell Death Differ</source><volume>23</volume><fpage>207</fpage><lpage>215</lpage><year>2015</year><pub-id pub-id-type="doi">10.1038/cdd.2015.85</pub-id><pub-id pub-id-type="pmid">26113043</pub-id></element-citation></ref>
<ref id="b32-etm-0-0-7969"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagi</surname><given-names>C</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Jaffer</surname><given-names>S</given-names></name><name><surname>Qiao</surname><given-names>R</given-names></name><name><surname>Keren</surname><given-names>R</given-names></name><name><surname>Triana</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Godbold</surname><given-names>J</given-names></name><name><surname>Bleiweiss</surname><given-names>IJ</given-names></name><name><surname>Hazan</surname><given-names>RB</given-names></name></person-group><article-title>N-cadherin expression in breast cancer: Correlation with an aggressive histologic variant-invasive micropapillary carcinoma</article-title><source>Breast Cancer Res Treat</source><volume>94</volume><fpage>225</fpage><lpage>235</lpage><year>2005</year><pub-id pub-id-type="doi">10.1007/s10549-005-7727-5</pub-id><pub-id pub-id-type="pmid">16258702</pub-id></element-citation></ref>
<ref id="b33-etm-0-0-7969"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Shan</surname><given-names>Z</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name></person-group><article-title>N-cadherin, a novel prognostic biomarker, drives malignant progression of colorectal cancer</article-title><source>Mol Med Rep</source><volume>12</volume><fpage>2999</fpage><lpage>3006</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/mmr.2015.3687</pub-id><pub-id pub-id-type="pmid">25936636</pub-id></element-citation></ref>
<ref id="b34-etm-0-0-7969"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Qian</surname><given-names>Q</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name></person-group><article-title>N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines</article-title><source>PLoS One</source><volume>8</volume><fpage>e57692</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0057692</pub-id><pub-id pub-id-type="pmid">23520479</pub-id></element-citation></ref>
<ref id="b35-etm-0-0-7969"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways</article-title><source>BMC Cancer</source><volume>17</volume><fpage>486</fpage><year>2017</year><pub-id pub-id-type="doi">10.1186/s12885-017-3475-2</pub-id><pub-id pub-id-type="pmid">28709407</pub-id></element-citation></ref>
<ref id="b36-etm-0-0-7969"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name></person-group><article-title>miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin &#x03B2;1 and matrix metalloproteinase 2 (MMP2)</article-title><source>PLoS One</source><volume>8</volume><fpage>e70192</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0070192</pub-id><pub-id pub-id-type="pmid">23936390</pub-id></element-citation></ref>
<ref id="b37-etm-0-0-7969"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Chao</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name></person-group><article-title>Association between MMP2-1306 C/T polymorphism and prostate cancer susceptibility: A meta-analysis based on 3906 subjects</article-title><source>Oncotarget</source><volume>8</volume><fpage>45020</fpage><lpage>45029</lpage><year>2017</year><pub-id pub-id-type="pmid">28445160</pub-id></element-citation></ref>
<ref id="b38-etm-0-0-7969"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name></person-group><article-title>Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9</article-title><source>PLoS One</source><volume>13</volume><fpage>e0190725</fpage><year>2018</year><pub-id pub-id-type="doi">10.1371/journal.pone.0190725</pub-id><pub-id pub-id-type="pmid">29300772</pub-id></element-citation></ref>
<ref id="b39-etm-0-0-7969"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name></person-group><article-title>miR-133b inhibits cell growth, migration, and invasion by targeting MMP9 in non-small cell lung cancer</article-title><source>Oncol Res</source><volume>25</volume><fpage>1109</fpage><lpage>1116</lpage><year>2016</year><pub-id pub-id-type="doi">10.3727/096504016X14800889609439</pub-id><pub-id pub-id-type="pmid">27938481</pub-id></element-citation></ref>
<ref id="b40-etm-0-0-7969"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Revert</surname><given-names>F</given-names></name><name><surname>Revert-Ros</surname><given-names>F</given-names></name><name><surname>Blasco</surname><given-names>R</given-names></name><name><surname>Artigot</surname><given-names>A</given-names></name><name><surname>L&#x00F3;pez-Pascual</surname><given-names>E</given-names></name><name><surname>Gozalbo-Rovira</surname><given-names>R</given-names></name><name><surname>Ventura</surname><given-names>I</given-names></name><name><surname>Guti&#x00E9;rrez-Carbonell</surname><given-names>E</given-names></name><name><surname>Roda</surname><given-names>N</given-names></name><name><surname>Ru&#x00ED;z-Sanchis</surname><given-names>D</given-names></name><etal/></person-group><article-title>Selective targeting of collagen IV in the cancer cell microenvironment reduces tumor burden</article-title><source>Oncotarget</source><volume>9</volume><fpage>11020</fpage><lpage>11045</lpage><year>2018</year><pub-id pub-id-type="doi">10.18632/oncotarget.24280</pub-id><pub-id pub-id-type="pmid">29541394</pub-id></element-citation></ref>
<ref id="b41-etm-0-0-7969"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>T</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer</article-title><source>Pharm Dev Technol</source><volume>23</volume><fpage>13</fpage><lpage>21</lpage><year>2016</year><pub-id pub-id-type="doi">10.1080/10837450.2016.1265553</pub-id><pub-id pub-id-type="pmid">27884084</pub-id></element-citation></ref>
<ref id="b42-etm-0-0-7969"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>C</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name></person-group><article-title>Klf4 inhibits tumor growth and metastasis by targeting microRNA-31 in human hepatocellular carcinoma</article-title><source>Int J Mol Med</source><volume>39</volume><fpage>47</fpage><lpage>56</lpage><year>2016</year><pub-id pub-id-type="doi">10.3892/ijmm.2016.2812</pub-id><pub-id pub-id-type="pmid">27909734</pub-id></element-citation></ref>
<ref id="b43-etm-0-0-7969"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Rong</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Qiu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name></person-group><article-title>PODXL, negatively regulated by KLF4, promotes the EMT and metastasis and serves as a novel prognostic indicator of gastric cancer</article-title><source>Gastric Cancer</source><volume>22</volume><fpage>48</fpage><lpage>59</lpage><year>2019</year><pub-id pub-id-type="doi">10.1007/s10120-018-0833-y</pub-id><pub-id pub-id-type="pmid">29748877</pub-id></element-citation></ref>
<ref id="b44-etm-0-0-7969"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>F</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>miR-543 promotes colorectal cancer proliferation and metastasis by targeting KLF4</article-title><source>Oncotarget</source><volume>8</volume><fpage>59246</fpage><lpage>59256</lpage><year>2017</year><pub-id pub-id-type="doi">10.18632/oncotarget.19495</pub-id><pub-id pub-id-type="pmid">28938633</pub-id></element-citation></ref>
<ref id="b45-etm-0-0-7969"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Zuo</surname><given-names>X</given-names></name><name><surname>Gagea</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Xie</surname><given-names>K</given-names></name></person-group><article-title>KLF4-mediated suppression of CD44 signaling negatively impacts pancreatic cancer stemness and metastasis</article-title><source>Cancer Res</source><volume>76</volume><fpage>2419</fpage><lpage>2431</lpage><year>2016</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-1691</pub-id><pub-id pub-id-type="pmid">26880805</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-etm-0-0-7969" position="float">
<label>Figure 1.</label>
<caption><p>IHC images of thyroid tumor tissue and paracarcinoma tissue. (A) Representative IHC image. Scale bar=50 &#x00B5;m. (B) Statistical analysis of immunohistochemistry results. Expression of KLF4 in thyroid tumor tissue and paracarcinoma tissue was detected by IHC. Compared with the adjacent non-cancerous tissues, the expression of KLF4 was significantly lower in thyroid tumor tissue (mean &#x00B1; standard deviation; n=3 per group). &#x002A;&#x002A;&#x002A;P&#x003C;0.001 vs. paracarcinoma tissue. IHC, immunohistochemistry; KLF4, Kruppel-like factor 4.</p></caption>
<graphic xlink:href="etm-18-05-3493-g00.tif"/>
</fig>
<fig id="f2-etm-0-0-7969" position="float">
<label>Figure 2.</label>
<caption><p>Western blot images of thyroid tumor tissue and paracarcinoma tissue. (A) Results of western blotting and (B) subsequent statistical analysis. The protein expression of KLF4 in tumor tissue and adjacent non-tumor tissue was detected via western blotting. The expression of KLF4 was markedly lower in thyroid tumor tissue compared with paracarcinoma tissue (mean &#x00B1; standard deviation; n=6 per group). &#x002A;P&#x003C;0.05 vs. paracarcinoma tissue. KLF4, Kruppel-like factor 4; T, tumor; P, paracarcinoma.</p></caption>
<graphic xlink:href="etm-18-05-3493-g01.tif"/>
</fig>
<fig id="f3-etm-0-0-7969" position="float">
<label>Figure 3.</label>
<caption><p>Confirmation of KLF4 overexpression. Papillary thyroid cancer KTC1 cells were transfected with viruses carrying KLF4 overexpression vectors. The relative expression of KLF4 was detected via quantitative PCR. The expression of KLF4 in KTC1 cells was significantly increased compared with the blank or negative control groups (mean &#x00B1; standard deviation; n=3 per group). &#x002A;&#x002A;&#x002A;P&#x003C;0.001 compared with the blank or negative control groups.</p></caption>
<graphic xlink:href="etm-18-05-3493-g02.tif"/>
</fig>
<fig id="f4-etm-0-0-7969" position="float">
<label>Figure 4.</label>
<caption><p>mRNA expression of N-cadherin, MMP2, MMP9 and collagen was significantly decreased in the KLF4 overexpression group. mRNA expression of E-cadherin, N-cadherin, Vimentin, MMP2, MMP9 and collagen in KTC1 cells were detected via quantitative PCR. Among all genes screened, the expression levels of N-cadherin, MMP2, MMP9 and collagen were significantly decreased in the KLF4 overexpression group, as compared with the blank or negative control groups (mean &#x00B1; standard deviation; n=3 per group). &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01 and &#x002A;&#x002A;&#x002A;P&#x003C;0.001 compared with the control or negative control group. MMP, matrix metalloproteinase; KLF4, Kruppel-like factor 4; COLLA, collagen; cad, cadherin.</p></caption>
<graphic xlink:href="etm-18-05-3493-g03.tif"/>
</fig>
<fig id="f5-etm-0-0-7969" position="float">
<label>Figure 5.</label>
<caption><p>Protein expression of N-cadherin, MMP2, MMP9 and collagen was significantly decreased in the KLF4 overexpression group. Protein expression of E-cadherin, N-cadherin, Vimentin, MMP2, MMP9 and collagen in KTC1 cells were detected via western blotting. The protein expression of N-cadherin, MMP2, MMP9 and collagen was significantly decreased in the KLF4 overexpression group compared with the blank or negative control groups (mean &#x00B1; standard deviation; n=3 per group). &#x002A;&#x002A;P&#x003C;0.01 and &#x002A;&#x002A;&#x002A;P&#x003C;0.001 vs. the control or negative control groups. MMP, matrix metalloproteinase; KLF4, Kruppel-like factor 4; COLLA, collagen; N-cad, N-cadherin.</p></caption>
<graphic xlink:href="etm-18-05-3493-g04.tif"/>
</fig>
<fig id="f6-etm-0-0-7969" position="float">
<label>Figure 6.</label>
<caption><p>Viability of papillary thyroid cancer cells was markedly decreased in the KLF4 overexpression group. The viability of KTC1 cells was detected using a cell counting kit-8 assay at 24, 48 and 72 h. The viability of KTC1 cells was markedly decreased in the KLF4 overexpression group at 24, 48 and 72 h when compared with the blank or negative control groups (mean &#x00B1; standard deviation; n=3 per group). &#x002A;&#x002A;P&#x003C;0.01 and &#x002A;&#x002A;&#x002A;P&#x003C;0.001 vs. the blank or negative control groups. KLF4, Kruppel-like factor 4.</p></caption>
<graphic xlink:href="etm-18-05-3493-g05.tif"/>
</fig>
<fig id="f7-etm-0-0-7969" position="float">
<label>Figure 7.</label>
<caption><p>Invasion of papillary thyroid cancer cells in the KLF4 overexpression group was markedly decreased. (A) Representative image of transwell invasion assay (magnification, &#x00D7;100). (B) Statistical analysis of the transwell invasion assay. Cell invasion ability was assessed using a transwell invasion assay. Compared with the negative control group, the invasion ability of KTC1 cells in the KLF4 overexpression group was markedly decreased (mean &#x00B1; standard deviation; n=3 per group). &#x002A;&#x002A;P&#x003C;0.01 vs. the negative control group. KLF4, Kruppel-like factor 4.</p></caption>
<graphic xlink:href="etm-18-05-3493-g06.tif"/>
</fig>
<fig id="f8-etm-0-0-7969" position="float">
<label>Figure 8.</label>
<caption><p>Migration ability of papillary thyroid cancer cells in the KLF4 overexpression group was markedly decreased at 24 h. (A) Representative image and (B) statistical analysis of the scratch migration assay. Cell migration was examined via a scratch migration assay at 0 and 24 h. Compared with the negative control group, the migration of KTC1 cells in the KLF4 overexpression group was markedly decreased at 24 h (mean &#x00B1; standard deviation; n=3 per group). &#x002A;&#x002A;P&#x003C;0.01 vs. the negative control group. KLF4, Kruppel-like factor 4.</p></caption>
<graphic xlink:href="etm-18-05-3493-g07.tif"/>
</fig>
<table-wrap id="tI-etm-0-0-7969" position="float">
<label>Table I.</label>
<caption><p>Clinicopathological features of patients in the present study.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Patient no.</th>
<th align="center" valign="bottom">1</th>
<th align="center" valign="bottom">2</th>
<th align="center" valign="bottom">3</th>
<th align="center" valign="bottom">4</th>
<th align="center" valign="bottom">5</th>
<th align="center" valign="bottom">6</th>
<th align="center" valign="bottom">7</th>
<th align="center" valign="bottom">8</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Age (years)</td>
<td align="center" valign="top">66</td>
<td align="center" valign="top">50</td>
<td align="center" valign="top">57</td>
<td align="center" valign="top">35</td>
<td align="center" valign="top">55</td>
<td align="center" valign="top">48</td>
<td align="center" valign="top">48</td>
<td align="center" valign="top">52</td>
</tr>
<tr>
<td align="left" valign="top">Sex</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">M</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">F</td>
<td align="center" valign="top">F</td>
</tr>
<tr>
<td align="left" valign="top">TNM</td>
<td align="center" valign="top">T1aN0M0</td>
<td align="center" valign="top">T1aN1M0</td>
<td align="center" valign="top">T1N1M0</td>
<td align="center" valign="top">T1aN1M0</td>
<td align="center" valign="top">T1aN1M0</td>
<td align="center" valign="top">T1aN0M0</td>
<td align="center" valign="top">T1bN0M0</td>
<td align="center" valign="top">T1bN0M0</td>
</tr>
<tr>
<td align="left" valign="top">Tumor stage</td>
<td align="center" valign="top">I</td>
<td align="center" valign="top">III</td>
<td align="center" valign="top">III</td>
<td align="center" valign="top">I</td>
<td align="center" valign="top">III</td>
<td align="center" valign="top">I</td>
<td align="center" valign="top">I</td>
<td align="center" valign="top">I</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-etm-0-0-7969"><p>F, female; M, male; TNM, tumor, node and metastasis. TNM classification (<xref rid="b22-etm-0-0-7969" ref-type="bibr">22</xref>). Tumor stage was determined according to the American Thyroid Association risk of recurrence staging system for initial assessment of risk of recurrence (<xref rid="b23-etm-0-0-7969" ref-type="bibr">23</xref>).</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tII-etm-0-0-7969" position="float">
<label>Table II.</label>
<caption><p>Primers for quantitative PCR.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Primer</th>
<th align="center" valign="bottom">Sequences (5&#x2032; to 3&#x2032;)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">KLF4-F</td>
<td align="left" valign="top">TTCCCATCTCAAGGCACACC</td>
</tr>
<tr>
<td align="left" valign="top">KLF4-R</td>
<td align="left" valign="top">CATGTGTAAGGCGAGGTGGT</td>
</tr>
<tr>
<td align="left" valign="top">MMP2-F</td>
<td align="left" valign="top">GATACCCCTTTGACGGTAAGGA</td>
</tr>
<tr>
<td align="left" valign="top">MMP2-R</td>
<td align="left" valign="top">CCTTCTCCCAAGGTCCATAGC</td>
</tr>
<tr>
<td align="left" valign="top">MMP9-F</td>
<td align="left" valign="top">GTACTCGACCTGTACCAGCG</td>
</tr>
<tr>
<td align="left" valign="top">MMP9-R</td>
<td align="left" valign="top">TTCAGGGCGAGGACCATAGA</td>
</tr>
<tr>
<td align="left" valign="top">Collagen I-F</td>
<td align="left" valign="top">AGTGGTTTGGATGGTGCCAA</td>
</tr>
<tr>
<td align="left" valign="top">Collagen I-R</td>
<td align="left" valign="top">GCACCATCATTTCCACGAGC</td>
</tr>
<tr>
<td align="left" valign="top">Vimentin (VIM)-F</td>
<td align="left" valign="top">TGGACCAGCTAACCAACGAC</td>
</tr>
<tr>
<td align="left" valign="top">Vimentin (VIM)-R</td>
<td align="left" valign="top">GCCAGAGACGCATTGTCAAC</td>
</tr>
<tr>
<td align="left" valign="top">E-cadherin (CDH1)-F</td>
<td align="left" valign="top">TCATGAGTGTCCCCCGGTAT</td>
</tr>
<tr>
<td align="left" valign="top">E-cadherin (CDH1)-R</td>
<td align="left" valign="top">TCTTGAAGCGATTGCCCCAT</td>
</tr>
<tr>
<td align="left" valign="top">N-cadherin (CDH2)-F</td>
<td align="left" valign="top">TGACAATGACCCCACAGCTC</td>
</tr>
<tr>
<td align="left" valign="top">N-cadherin (CDH2)-R</td>
<td align="left" valign="top">GTCCTGCTCACCACCACTAC</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
